Veracyte, Inc. (VCYT)
44.06
+2.59
(+6.25%)
USD |
NASDAQ |
Aug 25, 16:00
44.06
0.00 (0.00%)
After-Hours: 19:59
Veracyte Enterprise Value : 2.888B for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.888B |
| August 21, 2026 | 2.955B |
| August 20, 2026 | 2.913B |
| August 19, 2026 | 2.945B |
| August 18, 2026 | 2.824B |
| August 17, 2026 | 2.937B |
| August 14, 2026 | 2.870B |
| August 13, 2026 | 2.978B |
| August 12, 2026 | 3.146B |
| August 11, 2026 | 3.285B |
| August 10, 2026 | 3.273B |
| August 07, 2026 | 3.350B |
| August 06, 2026 | 3.264B |
| August 05, 2026 | 3.264B |
| August 04, 2026 | 3.285B |
| August 03, 2026 | 3.159B |
| July 31, 2026 | 3.277B |
| July 30, 2026 | 4.359B |
| July 29, 2026 | 4.032B |
| July 28, 2026 | 4.027B |
| July 27, 2026 | 4.024B |
| July 24, 2026 | 4.104B |
| July 23, 2026 | 4.206B |
| July 22, 2026 | 4.217B |
| July 21, 2026 | 4.339B |
| Date | Value |
|---|---|
| July 20, 2026 | 4.157B |
| July 17, 2026 | 4.307B |
| July 16, 2026 | 4.314B |
| July 15, 2026 | 4.337B |
| July 14, 2026 | 4.105B |
| July 13, 2026 | 4.174B |
| July 10, 2026 | 4.133B |
| July 09, 2026 | 4.320B |
| July 08, 2026 | 4.065B |
| July 07, 2026 | 4.068B |
| July 06, 2026 | 4.216B |
| July 02, 2026 | 4.142B |
| July 01, 2026 | 4.365B |
| June 30, 2026 | 4.275B |
| June 29, 2026 | 4.403B |
| June 26, 2026 | 4.427B |
| June 25, 2026 | 4.272B |
| June 24, 2026 | 4.129B |
| June 23, 2026 | 3.892B |
| June 22, 2026 | 3.844B |
| June 18, 2026 | 3.880B |
| June 17, 2026 | 3.693B |
| June 16, 2026 | 3.663B |
| June 15, 2026 | 3.522B |
| June 12, 2026 | 3.377B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Globus Medical, Inc. | 10.80B |
| Recursion Pharmaceuticals, Inc. | 1.251B |
| Anika Therapeutics, Inc. | 272.43M |
| Perspective Therapeutics, Inc. | 131.02M |
| Teleflex, Inc. | 8.418B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.49M |
| Revenue (Quarterly) | 150.32M |
| Total Expenses (Quarterly) | 124.83M |
| EPS Diluted (Quarterly) | 0.3106 |
| Gross Profit Margin (Quarterly) | 71.93% |
| Profit Margin (Quarterly) | 16.96% |
| Earnings Yield | 3.20% |
| Operating Earnings Yield | 2.71% |
| Normalized Earnings Yield | 2.928 |